Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

the prescribing decisions of physicians at Mochi Medical—and, as a result, engage in, and aid and abet, the unlawful corporate practice of medicine,” Lilly said in its complaint against Mochi.

Mass compounding of tirzepatide, the active ingredient in Mounjaro and Zepbound ... among other things, the prescribing decisions of physicians" and as a result engage in the "unlawful corporate ...

Mass compounding of tirzepatide, the active ingredient in Mounjaro and Zepbound ... the prescribing decisions of physicians" and as a result engage in the "unlawful corporate practice of medicine." ...